Aldosterone stimulates the cardiac Na +/H + exchanger via transactivation of the epidermal growth factor receptor

Hypertension

Volumn 58, Issue 5, 2011, Pages 912-919

  De Giusti, Verónica C ^a   Nolly, Mariela B ^a   Yeves, Alejandra M ^a   Caldiz, Claudia I ^a   Villa Abrille, María C ^a   De Cingolani, Gladys E Chiappe ^a   Ennis, Irene L ^a   Cingolani, Horacio E ^a   Aiello, Ernesto A ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Aldosterone; Cardiac myocytes; Epidermal growth factor receptor; Sodium hydrogen exchanger; Transactivation

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALDOSTERONE; CYCLOHEXIMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPLERENONE; MIFEPRISTONE; N 2 MERCAPTOPROPIONYL GLYCINE; REACTIVE OXYGEN METABOLITE; SODIUM PROTON EXCHANGE PROTEIN 1; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; EPIFLUORESCENCE MICROSCOPY; MOLECULE; MUSCLE CELL; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ALDOSTERONE; ANIMALS; CELLS, CULTURED; MODELS, ANIMAL; MYOCYTES, CARDIAC; PHOSPHORYLATION; RANDOM ALLOCATION; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SODIUM-HYDROGEN ANTIPORTER; SUPEROXIDES; TRANSCRIPTIONAL ACTIVATION;

EID: 83155183297     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.176024     Document Type: Article

References (59)

1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. (Pubitemid 36384098)
2. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction-Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15:79-87. (Pubitemid 32684565)
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure-Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. (Pubitemid 29407370)
4. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
5. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003;93:69-76. (Pubitemid 36859043)
6. Yoshida K, Kim-Mitsuyama S, Wake R, Izumiya Y, Izumi Y, Yukimura T, Ueda M, Yoshiyama M, Iwao H. Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res. 2005;28:447-455. (Pubitemid 41007460)
7. Diez J. Effects of aldosterone on the heart: beyond systemic hemodynamics? Hypertension. 2008;52:462-464.
8. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S. Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury. Hypertension. 2003;41:493-498. (Pubitemid 36314622)
9. Karmazyn M, Liu Q, Gan XT, Brix BJ, Fliegel L. Aldosterone increases NHE-1 expression and induces NHE-1-dependent hypertrophy in neonatal rat ventricular myocytes. Hypertension. 2003;42:1171-1176. (Pubitemid 37549073)
10. Barbato JC, Rashid S, Mulrow PJ, Shapiro JI, Franco-Saenz R. Mechanisms for aldosterone and spironolactone-induced positive inotropic actions in the rat heart. Hypertension. 2004;44:751-757. (Pubitemid 39435249)
11. Matsui S, Satoh H, Kawashima H, Nagasaka S, Niu CF, Urushida T, Katoh H, Watanabe Y, Hayashi H. Non-genomic effects of aldosterone on intracellular ion regulation and cell volume in rat ventricular myocytes. Can J Physiol Pharmacol. 2007;85:264-273. (Pubitemid 46846438)
12. + exchange in vascular smooth muscle cells by nongenomic and genomic mechanisms. Kidney Int. 1999;56: 1400-1412. (Pubitemid 29451247)
13. Cingolani HE, Perez NG, Caldiz CI, Garciarena CD, De Giusti VC, Correa MV, Villa-Abrille MC, Yeves AM, Ennis IL, Chiappe de Cingolani G, Aiello EA. Early hypertrophic signals after myocardial stretch: role of reactive oxygen species and the sodium/hydrogen exchanger. In: Kamkin A, Kiseleva I, eds. Mechanosensitivity in Cells and Tissues: Mechanosensitivy of the Heart. Moscow, Russia: Springer; 2010: 327-371.
14. Grossmann C, Gekle M. Non-classical actions of the mineralocorticoid receptor: misuse of EGF receptors? Mol Cell Endocrinol. 2007;277:6-12. (Pubitemid 47496192)
15. Grossmann C, Krug AW, Freudinger R, Mildenberger S, Voelker K, Gekle M. Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am J Physiol Endocrinol Metab. 2007;292:E1790-E1800. (Pubitemid 47084715)
16. Dorrance AM, Osborn HL, Grekin R, Webb RC. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol. 2001;281:R944-R950.
17. Grossmann C, Gekle M. Nongenotropic aldosterone effects and the EGFR: interaction and biological relevance. Steroids. 2008;73:973-978.
18. Grossmann C, Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol. 2009;308:53-62.
19. Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N. Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci. 2008;99:214-220. (Pubitemid 351228472)
20. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109:2792-2800. (Pubitemid 38737927)
21. Ai W, Zhang Y, Tang QZ, Yan L, Bian ZY, Liu C, Huang H, Bai X, Yin L, Li H. Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling. J Cell Biochem. 2010;110: 1111-1122.
22. Lui KE, Panchal AS, Santhanagopal A, Dixon SJ, Bernier SM. Epidermal growth factor stimulates proton efflux from chondrocytic cells. J Cell Physiol. 2002;192:102-112. (Pubitemid 34587392)
23. + exchanger activity in the human placental syncytiotrophoblast. Am J Physiol Regul Integr Comp Physiol. 2007;293:R2290-R2294. (Pubitemid 350224022)
24. + exchanger in podocytes through a mechanism that involves Janus kinase and calmodulin. Biochim Biophys Acta. 2009;1793:1174-1181.
25. + exchange by hydrogen peroxide in adult rat ventricular myocytes. Cardiovasc Res. 2002;53:470-480. (Pubitemid 34117698)
26. 2+-and protein kinase C-dependent mechanism. Am J Physiol Heart Circ Physiol. 2001;280:H1528-H1536.
27. De Giusti VC, Correa MV, Villa-Abrille MC, Beltrano C, Yeves AM, de Cingolani GE, Cingolani HE, Aiello EA. The positive inotropic effect of endothelin-1 is mediated by mitochondrial reactive oxygen species. Life Sci. 2008;83:264-271.
28. + exchanger by phosphodiesterase 5A inhibition is attributed to an increase in protein phosphatase activity. Hypertension. 2010;56:690-695.
29. Caldiz CI, Garciarena CD, Dulce RA, Novaretto LP, Yeves AM, Ennis IL, Cingolani HE, Chiappe de Cingolani G, Perez NG. Mitochondrial reactive oxygen species activate the slow force response to stretch in feline myocardium. J Physiol. 2007;584:895-905. (Pubitemid 350031930)
30. Huang S, Zhang A, Ding G, Chen R. Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation. Am J Physiol Renal Physiol. 2009;296:F1323-F1333.
31. Queisser N, Fazeli G, Schupp N. Superoxide anion and hydrogen peroxide-induced signaling and damage in angiotensin II and aldosterone action. Biol Chem. 391:1265-1279.
32. Ohmine T, Miwa Y, Takahashi-Yanaga F, Morimoto S, Maehara Y, Sasaguri T. The involvement of aldosterone in cyclic stretch-mediated activation of NADPH oxidase in vascular smooth muscle cells. Hypertens Res. 2009;32:690-699.
33. Zhu X, Manning RD Jr, Lu D, Gomez-Sanchez CE, Fu Y, Juncos LA, Liu R. Aldosterone stimulates superoxide production in the macula densa cells. Am J Physiol Renal Physiol. 2011;301:F529-F535.
34. Villa-Abrille MC, Caldiz CI, Ennis IL, Nolly MB, Casarini MJ, Chiappe de Cingolani GE, Cingolani HE, Perez NG. The Anrep effect requires transactivation of the epidermal growth factor receptor. J Physiol. 2010; 588:1579-1590.
35. Ganong WF, Mulrow PJ. Rate of change in sodium and potassium excretion after injection of aldosterone into the aorta and renal artery of the dog. Am J Physiol. 1958;195:337-342.
36. Spach C, Streeten DH. Retardation of sodium exchange in dog erythrocytes by physiological concentrations of aldosterone, in vitro. J Clin Invest. 1964;43:217-227.
37. 2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology. 2005;146:973-980. (Pubitemid 40289282)
38. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, Feldman RD. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension. 2011;57:442-451.
39. Krieg T, Cui L, Qin Q, Cohen MV, Downey JM. Mitochondrial ROS generation following acetylcholine-induced EGF receptor transactivation requires metalloproteinase cleavage of proHB-EGF. J Mol Cell Cardiol. 2004;36:435-443. (Pubitemid 38316948)
40. Krieg T, Landsberger M, Alexeyev MF, Felix SB, Cohen MV, Downey JM. Activation of Akt is essential for acetylcholine to trigger generation of oxygen free radicals. Cardiovasc Res. 2003;58:196-202. (Pubitemid 36351638)
41. Krieg T, Qin Q, McIntosh EC, Cohen MV, Downey JM. ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases. Am J Physiol Heart Circ Physiol. 2002;283: H2322-H2330. (Pubitemid 35345936)
42. Gekle M, Freudinger R, Mildenberger S, Silbernagl S. Aldosterone interaction with epidermal growth factor receptor signaling in MDCK cells. Am J Physiol Renal Physiol. 2002;282:F669-F679. (Pubitemid 34654514)
43. D'Autreaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol. 2007;8:813-824. (Pubitemid 47462134)
44. + exchange in neonatal rat cardiac myocytes. Circ Res. 1998;82: 1053-1062. (Pubitemid 28249066)
45. Cingolani HE, Villa-Abrille MC, Cornelli M, Nolly A, Ennis IL, Garciarena C, Suburo AM, Torbidoni V, Correa MV, Camilionde Hurtado MC, Aiello EA. The positive inotropic effect of angiotensin II: role of endothelin-1 and reactive oxygen species. Hypertension. 2006;47: 727-734. (Pubitemid 43740245)
46. Wetzker R, Bohmer FD. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol. 2003;4:651-657. (Pubitemid 36934967)
47. Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B, Gekle M. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol. 2005;19:1697-1710. (Pubitemid 41007884)
48. Perrella MA, Maki T, Prasad S, Pimental D, Singh K, Takahashi N, Yoshizumi M, Alali A, Higashiyama S, Kelly RA, Lee ME, Smith TW. Regulation of heparin-binding epidermal growth factor-like growth factor mRNA levels by hypertrophic stimuli in neonatal and adult rat cardiac myocytes. J Biol Chem. 1994;269:27045-27050. (Pubitemid 24332908)
49. Ushikoshi H, Takahashi T, Chen X, Khai NC, Esaki M, Goto K, Takemura G, Maruyama R, Minatoguchi S, Fujiwara T, Nagano S, Yuge K, Kawai T, Murofushi Y, Fujiwara H, Kosai K. Local overex-pression of HB-EGF exacerbates remodeling following myocardial infarction by activating noncardiomyocytes. Lab Invest. 2005;85: 862-873. (Pubitemid 41021295)
50. Zhai P, Galeotti J, Liu J, Holle E, Yu X, Wagner T, Sadoshima J. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ Res. 2006;99:528-536. (Pubitemid 44337825)
51. Fardella CCC, Mosso L. Primary hyperaldosteronism in the hypertensive disease. Curr Hypertens Rev. 2006;2:36-40.
52. Stehr CB, Mellado R, Ocaranza MP, Carvajal CA, Mosso L, Becerra E, Solis M, Garcia L, Lavandero S, Jalil J, Fardella CE. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens. 28:2120-2126.
53. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248. (Pubitemid 40523144)
54. Martinez FA. Aldosterone inhibition and cardiovascular protection: more important than it once appeared. Cardiovasc Drugs Ther. 2010;24: 345-350.
55. Cingolani HE, Ennis IL. Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation. 2007;115: 1090-1100. (Pubitemid 46673171)
56. +-exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling. Br J Pharmacol. 2008;154: 1266-1275. (Pubitemid 351992061)
57. i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res. 2003; 57:1015-1024. (Pubitemid 36324606)
58. +- exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure. Cardiovasc Res. 2005;65:83-92. (Pubitemid 40038481)
59. 2+ signals that induce cardiac hypertrophy and heart failure. Circ Res. 2008;103: 891-899.